NPF Submits Letter in Support of Maryland All Copays Count Legislation

01/20/2021

The NPF is the leading patient advocacy group for over 8.3 million Americans and the more than 152,000 Marylanders living with psoriasis and psoriatic arthritis. I write to you today to express NPF’s support for HB 167, Out-of-Pocket Maximums and Cost-Sharing Requirements – Calculation and respectfully request you vote HB 167 out of committee.

A 2020 NPF survey found that only 3 in 10 people with psoriatic disease with incomes between $50,000 and $99,999 could afford their treatments without copay assistance. During this current pandemic, NPF is concerned that the Marylanders living with psoriasis and psoriatic arthritis are potentially at higher risk of complications or death from COVID-19. It is of utmost importance that unnecessary barriers to the appropriate treatments are removed for patients – such as high out-of-pocket costs.

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


The National Psoriasis Foundation is a qualified 501(c)(3) EIN 93-0571472.


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.